To evaluate the possible association between TPX2 expression and the outcome of patients with tumors carrying MYCN amplification and tumors with MYCN single copy, the two NB patient groups were stratified by the presence or lack of amplified MYCN. Patients with high TPX2 gene expression had reduced event-free and overall survival in groups with both MYCN amplified and non-amplified tumors (Figure 8A), but these trends did not reach statistical significance. This evidence concerns the gene MYCN and neuroblastoma.